FACULTY
David Eichenbaum, MD, FAAO
Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida
St. Petersburg, FL
PROGRAM OVERVIEW
This podcast series aims to increase the target clinicians’ awareness of gaps and burdens associated with treatment of ocular disorders such as nAMD and DME, contributing to poorer vision outcomes. Learn about unmet needs in the treatment of nAMD and DME, enhance appreciation of barriers to anti-VEGF treatment, and acquire tactics to address these barriers through individualized approaches to treatment such as dosing strategies and next-generation anti-VEGF therapy.
TARGET AUDIENCE
This initiative is designed to meet the educational needs of retina specialists, comprehensive ophthalmologists, and retina fellows involved in the management of patients with retinal vascular disease.
LEARNING OBJECTIVES
- Evaluate adherence barriers in nAMD and DME treatment, including injection frequency and patient factors
- Analyze the duration of effectiveness in established and emerging therapies for nAMD and DME
- Identify patients eligible for dosing modifications or transitioning to longer-lasting therapies, based on individual, treatment, and disease considerations
- Apply personalized treatment selection and dosing strategies to optimize care for nAMD and DME patients
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
David Eichenbaum, MD discloses the following:
- Speakers’ Bureau: Alimera, Allergan, Apellis, Astellas, Bayer, Genentech, Regeneron Pharmaceuticals, Inc.
- Consultant: 4DMT, Alimera, Allergan, Amaros, Annexon, Apellis, Astellas, Bausch & Lomb, Bayer, Coherus, CorEvitas/Vestrum, Complement Therapeutics, Crinetics, EyePoint, Genentech, Harrow, Kodiak, Neurotech, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Outlook, RecensMedica, Regeneron Pharmaceuticals, Inc., Regenxbio, ReVive, RetinAI, Roche, Samsara, Stealth, and Tilak
- Investigator: 4DMT, Aerie/Alcon, Alexion, Annexon, Astellas, Aviceda, Bayer, EyeBio, EyePoint, Gemini, Genentech, Gyroscope, Ionis, Janssen, Kodiak, Kyowa Kirin, Mylan, NGM, Novartis, Ocular Therapeutix, OcuTerra, Opthea, ONL, Priovant, RecensMedica, Regeneron Pharmaceuticals, Inc., Regenxbio, Roche, Stealth, and Unity
- Equity/Stockholder/Options: Amaros, Boston Image Reading Center, Janssen, Network Eye, ReVive, and US Retina
- Founder: Network Eye
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Sharon Windsor Harker, Medical Director of Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this activity. To receive CME/CNE credit participants must:
- Read the CME information and faculty disclosures.
- Complete the pre-test before listening.
- Participate in the activity by listening to the podcast.
- Complete online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
Please listen to the podcast below:
RELEASED DATE: October 01, 2024
EXPIRATION DATE: October 01, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
David Eichenbaum, MD, FAAO
Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida
St. Petersburg, FL
Faculty
Priya Vakharia, MD
Collaborative Assistant Professor
University of South Florida College of Medicine
St. Petersburg, FL
PROGRAM OVERVIEW
This podcast series aims to increase the target clinicians’ awareness of gaps and burdens associated with treatment of ocular disorders such as nAMD and DME, contributing to poorer vision outcomes. Learn about unmet needs in the treatment of nAMD and DME, enhance appreciation of barriers to anti-VEGF treatment, and acquire tactics to address these barriers through individualized approaches to treatment such as dosing strategies and next-generation anti-VEGF therapy.
TARGET AUDIENCE
This initiative is designed to meet the educational needs of retina specialists, comprehensive ophthalmologists, and retina fellows involved in the management of patients with retinal vascular disease.
LEARNING OBJECTIVES
- Evaluate adherence barriers in nAMD and DME treatment, including injection frequency and patient factors
- Analyze the duration of effectiveness in established and emerging therapies for nAMD and DME
- Identify patients eligible for dosing modifications or transitioning to longer-lasting therapies, based on individual, treatment, and disease considerations
- Apply personalized treatment selection and dosing strategies to optimize care for nAMD and DME patients
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
David Eichenbaum, MD discloses the following:
- Speakers’ Bureau: Alimera, Allergan, Apellis, Astellas, Bayer, Genentech, Regeneron Pharmaceuticals, Inc.
- Consultant: 4DMT, Alimera, Allergan, Amaros, Annexon, Apellis, Astellas, Bausch & Lomb, Bayer, Coherus, CorEvitas/Vestrum, Complement Therapeutics, Crinetics, EyePoint, Genentech, Harrow, Kodiak, Neurotech, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Outlook, RecensMedica, Regeneron Pharmaceuticals, Inc., Regenxbio, ReVive, RetinAI, Roche, Samsara, Stealth, and Tilak
- Investigator: 4DMT, Aerie/Alcon, Alexion, Annexon, Astellas, Aviceda, Bayer, EyeBio, EyePoint, Gemini, Genentech, Gyroscope, Ionis, Janssen, Kodiak, Kyowa Kirin, Mylan, NGM, Novartis, Ocular Therapeutix, OcuTerra, Opthea, ONL, Priovant, RecensMedica, Regeneron Pharmaceuticals, Inc., Regenxbio, Roche, Stealth, and Unity
- Equity/Stockholder/Options: Amaros, Boston Image Reading Center, Janssen, Network Eye, ReVive, and US Retina
- Founder: Network Eye
Priya Vakharia, MD discloses the following:
- Speakers’ Bureau: Apellis, Astellas, Genentech, and Regeneron Pharmaceuticals, Inc.
- Consulting: AbbVie, Alimera, Annexon, Apellis, Astellas, Bayer, Coherus, Genentech, Regeneron Pharmaceuticals, Inc., Novartis, Bausch and Lomb, Eyepoint, Notal Vision, and Ocuphire
- Contracted Research: 4DMT, Alexion, Allgenesis, Aviceda, Ionis, Janssen, Kodiak, Kirwin, Kyoto, Ocular Therapeutics, Ocuterra, Ophthea, ONL Therapeutics, and Pfizer
- Investigator: Astellas, Annexon, Bayer, RegenxBio, Stealth Biotherapeutics, Unity, Genentech, Regeneron Pharmaceuticals, Inc., Eyepoint, Recens Medical, and Novartis
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Sharon Windsor Harker, Medical Director of Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this activity. To receive CME/CNE credit participants must:
- Read the CME information and faculty disclosures.
- Complete the pre-test before listening.
- Participate in the activity by listening to the podcast.
- Complete online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
Please listen to the podcast below:
RELEASED DATE: October 11, 2024
EXPIRATION DATE: October 11, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
David Eichenbaum, MD, FAAO
Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida
St. Petersburg, FL
Faculty
Srinivas R. Sadda, MD
Professor of Ophthalmology
Doheny Eye Institute
David Geffen School of Medicine
University of California-Los Angeles
Pasadena, CA
PROGRAM OVERVIEW
This podcast series aims to increase the target clinicians’ awareness of gaps and burdens associated with treatment of ocular disorders such as nAMD and DME, contributing to poorer vision outcomes. Learn about unmet needs in the treatment of nAMD and DME, enhance appreciation of barriers to anti-VEGF treatment, and acquire tactics to address these barriers through individualized approaches to treatment such as dosing strategies and next-generation anti-VEGF therapy.
TARGET AUDIENCE
This initiative is designed to meet the educational needs of retina specialists, comprehensive ophthalmologists, and retina fellows involved in the management of patients with retinal vascular disease.
LEARNING OBJECTIVES
- Evaluate adherence barriers in nAMD and DME treatment, including injection frequency and patient factors
- Analyze the duration of effectiveness in established and emerging therapies for nAMD and DME
- Identify patients eligible for dosing modifications or transitioning to longer-lasting therapies, based on individual, treatment, and disease considerations
- Apply personalized treatment selection and dosing strategies to optimize care for nAMD and DME patients
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
David Eichenbaum, MD discloses the following:
- Speakers’ Bureau: Alimera, Allergan, Apellis, Astellas, Bayer, Genentech, Regeneron Pharmaceuticals, Inc.
- Consultant: 4DMT, Alimera, Allergan, Amaros, Annexon, Apellis, Astellas, Bausch & Lomb, Bayer, Coherus, CorEvitas/Vestrum, Complement Therapeutics, Crinetics, EyePoint, Genentech, Harrow, Kodiak, Neurotech, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Outlook, RecensMedica, Regeneron Pharmaceuticals, Inc., Regenxbio, ReVive, RetinAI, Roche, Samsara, Stealth, and Tilak
- Investigator: 4DMT, Aerie/Alcon, Alexion, Annexon, Astellas, Aviceda, Bayer, EyeBio, EyePoint, Gemini, Genentech, Gyroscope, Ionis, Janssen, Kodiak, Kyowa Kirin, Mylan, NGM, Novartis, Ocular Therapeutix, OcuTerra, Opthea, ONL, Priovant, RecensMedica, Regeneron Pharmaceuticals, Inc., Regenxbio, Roche, Stealth, and Unity
- Equity/Stockholder/Options: Amaros, Boston Image Reading Center, Janssen, Network Eye, ReVive, and US Retina
- Founder: Network Eye
Srinivas R. Sadda, MD discloses the following:
- Consulting: Amgen, Alylam, AbbVie, Allergan, Apellis, Alexion, Astellas, Iveric Bio, Biogen, Boehringer Ingelheim, Character, Regeneron Pharmaceuticals, Inc., Roche, Novartis, ONL, NGM Bio, Neurotech, Heidelberg, Topcon, Optos, NotalVision, Iberian, and iCare
- DMSC: RegenxBio and Regeneron Pharmaceuticals, Inc.
- Research Instruments: Carl Zeiss Meditec, Optos, Topcon, iCare, Nidek, Heidelberg, and NotalVision
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Sharon Windsor Harker, Medical Director of Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this activity. To receive CME/CNE credit participants must:
- Read the CME information and faculty disclosures.
- Complete the pre-test before listening.
- Participate in the activity by listening to the podcast.
- Complete online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
Please listen to the podcast below:
RELEASED DATE: October 11, 2024
EXPIRATION DATE: October 11, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
David Eichenbaum, MD, FAAO
Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida
St. Petersburg, FL
Faculty
Sumit Sharma, MD
Retina and Uveitis Specialist
Uveitis Fellowship Director
Assistant Professor of Ophthalmology
Cleveland Clinic’s Cole Eye Institute
Cleveland, OH
PROGRAM OVERVIEW
This podcast series aims to increase the target clinicians’ awareness of gaps and burdens associated with treatment of ocular disorders such as nAMD and DME, contributing to poorer vision outcomes. Learn about unmet needs in the treatment of nAMD and DME, enhance appreciation of barriers to anti-VEGF treatment, and acquire tactics to address these barriers through individualized approaches to treatment such as dosing strategies and next-generation anti-VEGF therapy.
TARGET AUDIENCE
This initiative is designed to meet the educational needs of retina specialists, comprehensive ophthalmologists, and retina fellows involved in the management of patients with retinal vascular disease.
LEARNING OBJECTIVES
- Evaluate adherence barriers in nAMD and DME treatment, including injection frequency and patient factors
- Analyze the duration of effectiveness in established and emerging therapies for nAMD and DME
- Identify patients eligible for dosing modifications or transitioning to longer-lasting therapies, based on individual, treatment, and disease considerations
- Apply personalized treatment selection and dosing strategies to optimize care for nAMD and DME patients
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
David Eichenbaum, MD discloses the following:
- Speakers’ Bureau: Alimera, Allergan, Apellis, Astellas, Bayer, Genentech, Regeneron Pharmaceuticals, Inc.
- Consultant: 4DMT, Alimera, Allergan, Amaros, Annexon, Apellis, Astellas, Bausch & Lomb, Bayer, Coherus, CorEvitas/Vestrum, Complement Therapeutics, Crinetics, EyePoint, Genentech, Harrow, Kodiak, Neurotech, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Outlook, RecensMedica, Regeneron Pharmaceuticals, Inc., Regenxbio, ReVive, RetinAI, Roche, Samsara, Stealth, and Tilak
- Investigator: 4DMT, Aerie/Alcon, Alexion, Annexon, Astellas, Aviceda, Bayer, EyeBio, EyePoint, Gemini, Genentech, Gyroscope, Ionis, Janssen, Kodiak, Kyowa Kirin, Mylan, NGM, Novartis, Ocular Therapeutix, OcuTerra, Opthea, ONL, Priovant, RecensMedica, Regeneron Pharmaceuticals, Inc., Regenxbio, Roche, Stealth, and Unity
- Equity/Stockholder/Options: Amaros, Boston Image Reading Center, Janssen, Network Eye, ReVive, and US Retina
- Founder: Network Eye
Sumit Sharma, MD discloses the following:
- Consultant: Alimera, Abbvie, Apellis, Bausch and Lomb, Clearside, Eyepoint, Genentech/Roche, Iveric Bio, Kodiak, Regeneron Pharmaceuticals, Inc., RegenXBio, Ripple, Volk, and Zeiss
- Contracted Research: Acelyrin, Gilead, Genentech/Roche, Santen, IONIS, and Kodiak
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Sharon Windsor Harker, Medical Director of Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this activity. To receive CME/CNE credit participants must:
- Read the CME information and faculty disclosures.
- Complete the pre-test before listening.
- Participate in the activity by listening to the podcast.
- Complete online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
Please listen to the podcast below:
RELEASED DATE: October 11, 2024
EXPIRATION DATE: October 11, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
